Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Open-label Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of GTAEXS617 in Patients With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1/2 Open-label Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of GTAEXS617 in Patients With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs REC 617 (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Colorectal cancer; Head and neck cancer; HER2 negative breast cancer; Male breast cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms ELUCIDATE
  • Sponsors Exscientia

Most Recent Events

  • 09 Dec 2024 According to Recursion Pharmaceuticals media release, company will also hold a webinar on December 10 to present the preliminary data broadcast from Recursion's X, LinkedIn, and YouTube accounts. And In parallel to the ongoing monotherapy dose escalation (QD and BID), combination studies are expected to initiate in H1, 2025. The company expects to present additional ELUCIDATE data at future medical events.
  • 09 Dec 2024 According to Recursion Pharmaceuticals media release, Interim results from Phase 1 clinical data for REC-617 Monotherapy presented at an AACR Special Conference in Cancer Research.
  • 18 Jul 2024 According to Exscientia media release, Exscientia plc today announced it has reached an agreement to acquire GT Apeirons share of its oral CDK7 inhibitor programme, gaining full control of GTAEXS617 (617) and all related intellectual property.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top